Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097312 · ClinicalTrials.gov registry record
PREHEVBRIO Pregnancy Outcomes Registry
A clinical trial of Vaccine Exposure During Pregnancy, sponsored by VBI Vaccines.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT06097312: Recruiting study of Vaccine Exposure During Pregnancy, sponsored by VBI Vaccines.
NCT06097312 is a study of Vaccine Exposure During Pregnancy that is actively recruiting participants, run by VBI Vaccines. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06097312, a study of Vaccine Exposure During Pregnancy, is actively recruiting participants, sponsored by VBI Vaccines.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The registry is an observational surveillance program designed to recruit and encourage participation of women who were exposed to PREHEVBRIO® hepatitis B vaccine during pregnancy and to collect and analyze information related to post-exposure pregnancy and fetal and neonatal outcomes. The objective of the Registry is to monitor and evaluate all received reports of PREHEVBRIO® vaccine exposure within 28 days prior to conception or at any time during pregnancy and delivery, as well as maternal, obstetrical, pregnancy, fetal and neonatal outcomes. This registry is primarily descriptive and designed to detect potential safety signals rather than test hypotheses.
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
Kansas
- ProPharma, Recruiting Nationwide - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2032-03-31 |
What NCT06097312 shows while recruiting
NCT06097312 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Vaccine Exposure During Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT06097312 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06097312 about?
NCT06097312 is a clinical study titled "PREHEVBRIO Pregnancy Outcomes Registry". The registry is an observational surveillance program designed to recruit and encourage participation of women who were exposed to PREHEVBRIO® hepatitis B vaccine during pregnancy and to collect and analyze information related to post-exposure pregnancy and fetal and neonatal outcomes. The objectiv...
What is the current status of trial NCT06097312?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2023-11-30. Estimated completion is 2032-03-31.
What conditions does trial NCT06097312 study?
This clinical trial studies the following conditions: Vaccine Exposure During Pregnancy.
What interventions are being tested in trial NCT06097312?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT06097312?
This trial is sponsored by VBI Vaccines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06097312 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccine Exposure During Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI